China approves first invasive brain-computer interface chip: what's next?

China approved for clinical use the world's first invasive implantable chip for the human brain for brain-computer interface (BCI) — this is how the story begins in MIT Technology Review's daily newsletter The Download. At the center of the story is a resident of Henan Province named Dong Hui, who in October, sitting in the courtyard of his own house, decided to try this technology.

What is an invasive brain-computer interface

Brain-computer interfaces are divided into non-invasive — for example, electroencephalography helmets that read signals through the scalp — and invasive, requiring surgical implantation of electrodes directly into brain tissue or on its surface. Invasive systems provide incomparably cleaner and more accurate signals, since electrodes are in direct contact with neurons, rather than detecting weakened and distorted activity from outside the skull. This is why such devices are usually considered for people with severe motor disorders — paralysis, consequences of stroke or spinal cord injuries — for whom BCI can restore the ability to control a computer, prosthetic limb or wheelchair using thought alone, bypassing damaged nerve pathways.

Why approval in China is a significant milestone

Regulatory approval of an invasive chip means the transition of the technology from the stage of experimental clinical trials to the stage of available medical application — that is, the device can now be implanted in patients outside a narrow circle of research protocols. Until now, the leading developments in this field — primarily Elon Musk's Neuralink company in the US — remained at the clinical trial stage with a limited number of patients. Approval of the Chinese analog signals that in the race to commercialize invasive neurointerfaces, China may be moving faster than Western competitors, relying on its own regulatory and research base.

Key details known at the moment:

• Location of approval — China, the world's first regulatory approval of an invasive BCI chip.
• Location of the story — Henan Province.
• The story's subject — a patient named Dong Hui.
• Publication — MIT Technology Review, publication in The Download newsletter.

What this means for the future of neurotechnology

The technology of brain-computer interfaces has long been perceived as experimental and extremely niche, available only to a handful of patients as part of clinical trials in the best medical centers in the world. The transition to regulatory approval is the first step toward making such devices part of standard medical practice, available to a much wider range of patients with motor disorders. At the same time, it raises questions that remain far from final resolution: long-term safety of electrode implantation in the brain, risks of infection and tissue rejection, cost of the operation and subsequent device maintenance, as well as ethical boundaries for using the technology beyond strictly medical indications.

For the global neurotechnology race, Chinese approval could become a signal of acceleration: if one major player demonstrates a path to commercial approval of invasive chips, competitors — primarily American companies like Neuralink and Synchron, as well as research groups in Europe — will face additional pressure to accelerate their own regulatory processes and clinical programs without sacrificing patient safety standards.

The path from a laboratory prototype to a regulatory-approved medical device for invasive neurotechnologies usually takes years and goes through sequential phases of clinical trials, in which basic safety of implantation is first checked on a small group of patients, and then — effectiveness and long-term signal stability on a wider sample. This is why the transition to the status of a device approved for clinical use is considered a significant milestone, not a routine event: it means that the regulator — in this case Chinese — found the accumulated data sufficient to allow wider use of the technology outside research centers that participated in the initial trials. Publication of such news in The Download newsletter also emphasizes that MIT Technology Review's editors view the development of BCI technologies not as a narrow medical topic, but as part of a broader picture of technological progress, comparable to achievements in generative AI and robotics.